-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OK3Wj59eL3fQGrNiX0JOY3oJAEoKJN+f9IeAfe7zWZje4IUeXt397OHluvz9Xem1 Vb4p+BpLdbutOnWqI6pC9A== 0000950135-07-003768.txt : 20070620 0000950135-07-003768.hdr.sgml : 20070620 20070620145418 ACCESSION NUMBER: 0000950135-07-003768 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070620 DATE AS OF CHANGE: 20070620 GROUP MEMBERS: PETER KOLCHINSKY GROUP MEMBERS: RA CAPITAL BIOTECH FUND, L.P. GROUP MEMBERS: RICHARD H. ALDRICH SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AP PHARMA INC /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-39444 FILM NUMBER: 07931123 BUSINESS ADDRESS: STREET 1: 123 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 6503662626 MAIL ADDRESS: STREET 1: 123 SAGINAW DRIVE STREET 2: 123 SAGINAW DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: RA CAPITAL MANAGEMENT, LLC CENTRAL INDEX KEY: 0001346824 IRS NUMBER: 830406777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 111 HUNTINGTON AVE, SUITE 610 CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-778-2512 MAIL ADDRESS: STREET 1: 111 HUNTINGTON AVE, SUITE 610 CITY: BOSTON STATE: MA ZIP: 02199 SC 13G 1 b65794rasc13g.htm RA CAPITAL MANAGEMENT LLC sc13g
 

     
 
OMB APPROVAL
  
 
OMB Number: 3235-0145
  
 
Expires: February 28, 2009
  
 
Estimated average burden hours per response...10.4
  
 
 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)
Information to be Included in Statements Filed Pursuant to Rules 13d-1(b), (c) and (d) and Amendments
Thereto Filed Pursuant to Rule 13d-2(b)

Under the Securities Exchange Act of 1934
(Amendment No. )*

A.P. Pharma, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
00202J104
(CUSIP Number)
June 13, 2007
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     þ Rule 13d-1(c)

     o Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
2 
   of   
9  

 

           
1   NAMES OF REPORTING PERSONS:
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
    RA Capital Management, LLC
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   0
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   2,424,242
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   0
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    2,424,242
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  2,424,242
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  8.8%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IA
* SEE INSTRUCTIONS BEFORE FILLING OUT.

 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
3 
   of   
9  

 

           
1   NAMES OF REPORTING PERSONS:
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
    Richard H. Aldrich
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  USA
       
  5   SOLE VOTING POWER:
     
NUMBER OF   -0-
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   2,424,242
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   -0-
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    2,424,242
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  2,424,242
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  8.8%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN
* SEE INSTRUCTIONS BEFORE FILLING OUT.

 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
4 
   of   
9  

 

           
1   NAMES OF REPORTING PERSONS:
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
    Peter Kolchinsky
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  USA
       
  5   SOLE VOTING POWER:
     
NUMBER OF   -0-
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   2,424,242
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   -0-
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    2,424,242
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  2,424,242
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  8.8%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  IN
* SEE INSTRUCTIONS BEFORE FILLING OUT.

 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
5 
   of   
9  

 

           
1   NAMES OF REPORTING PERSONS:
   
  I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY): 
    RA Capital Biotech Fund, L.P.
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
  (a)   o
  (b)   o
     
3   SEC USE ONLY:
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION:
   
  Delaware
       
  5   SOLE VOTING POWER:
     
NUMBER OF   -0-
       
SHARES 6   SHARED VOTING POWER:
BENEFICIALLY    
OWNED BY   2,381,576
       
EACH 7   SOLE DISPOSITIVE POWER:
REPORTING    
PERSON   -0-
       
WITH: 8   SHARED DISPOSITIVE POWER:
     
    2,381,576
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
   
  2,381,576
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):
   
  8.6%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):
   
  PN
* SEE INSTRUCTIONS BEFORE FILLING OUT.

 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
6 
   of   
9  
Item 1(a)   Name of Issuer:
          The name of the issuer is A.P. Pharma, Inc. (the “Issuer”).
Item 1(b)   Address of Issuer’s Principal Executive Offices:
          The Company’s principal executive office is located at 123 Saginaw Drive, Redwood City, CA 94063.
Item 2(a)   Name of Person Filing:
          This joint statement on Schedule 13G is being filed by Richard H. Aldrich, Peter Kolchinsky, RA Capital Management, LLC and RA Capital Biotech Fund, L.P., who are collectively referred to as the “Reporting Persons.” Mr. Aldrich and Mr. Kolchinsky (together, the “Managers”) are the managers of RA Capital Management, LLC (“Capital”), which is the sole general partner of RA Capital Biotech Fund, L.P. (“Fund I”).
          The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit A (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.
Item 2(b)   Address of Principal Business Office or, if none, Residence:
          The address of the principal business office of each of the Reporting Persons is 111 Huntington Avenue, Suite 610, Boston, MA 02199.
Item 2(c)   Citizenship:
          Capital is a Delaware limited liability company. Fund I is a Delaware limited partnership. The Managers are U.S. citizens.
Item 2(d)   Title of Class of Securities:
          Common Stock, par value $0.01 per share (the “Common Stock”).
Item 2(e)   CUSIP No.:
          00202J104
Item 3   If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:
          Not Applicable.
Item 4   Ownership:
          Capital and each of the Managers each beneficially owns 2,424,242 shares of Common Stock, representing 8.8% of the class, and consisting of 2,381,576 shares of Common Stock beneficially owned by Fund I and 42,666 shares of Common Stock beneficially owned by RA Capital Biotech Fund II, L.P. (“Fund II” and, together with Fund I, the “Funds”), which is not a Reporting Person. Capital is the sole general partner of Fund II.
          Fund I beneficially owns 2,381,576 shares of Common Stock, representing 8.6% of the class.

 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
7 
   of   
9  
          Fund I has the shared power to vote and dispose of the shares of Common Stock beneficially owned by it. Capital, as the sole general partner of each of the Funds, has the shared power to vote and dispose of all of the shares of Common Stock reported in this Schedule 13G. Each Manager, by virtue of his position as a manager of Capital, has the shared power to vote and dispose of all of the shares of Common Stock reported in this Schedule 13G.
Item 5   Ownership of Five Percent or Less of a Class:
          Not applicable.
Item 6   Ownership of More Than Five Percent on Behalf of Another Person:
          See Item 4.
Item 7   Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:
          Not applicable.
Item 8   Identification and Classification of Members of the Group:
          Not applicable.
Item 9   Notice of Dissolution of Group:
          Not applicable.
Item 10   Certification:
          By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as participant in any transaction having that purpose or effect.

 

 

                     
CUSIP No.
  
00202J104 
 13G Page  
8 
   of   
9  
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
             
 
  Date:   June 20, 2007    
 
            
    RA CAPITAL MANAGEMENT, LLC
 
            
 
  By:   /s/ Richard H. Aldrich    
 
     
 
Richard H. Aldrich 		   
 
      Manager    
 
            
    RA CAPITAL BIOTECH FUND, L.P.
 
            
 
  By:   RA Capital Management, LLC    
 
      General Partner    
 
            
 
  By:   /s/ Richard H. Aldrich    
 
     
 
Richard H. Aldrich 		   
 
      Manager    
 
            
    RICHARD H. ALDRICH
 
            
    /s/ Richard H. Aldrich
         
    Richard H. Aldrich
 
            
    PETER KOLCHINSKY
 
            
    /s/ Peter Kolchinsky
         
    Peter Kolchinsky

 

 

Exhibit A
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G
The undersigned hereby agree as follows:
     (i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and
     (ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.
Date: June 20, 2007
             
    RA CAPITAL MANAGEMENT, LLC
 
            
 
  By:   /s/ Richard H. Aldrich
 
Richard H. Aldrich 		   
 
      Manager    
 
            
    RA CAPITAL BIOTECH FUND, L.P.
 
            
 
  By:   RA Capital Management, LLC    
 
      General Partner    
 
            
 
  By:   /s/ Richard H. Aldrich
 
Richard H. Aldrich 		   
 
      Manager    
 
            
    RICHARD H. ALDRICH
 
            
    /s/ Richard H. Aldrich
           
    Richard H. Aldrich
 
            
    PETER KOLCHINSKY
 
            
    /s/ Peter Kolchinsky
           
    Peter Kolchinsky

 

-----END PRIVACY-ENHANCED MESSAGE-----